NCT03891485View on ClinicalTrials.gov

Nivolumab in mRCC Patients: Treg Function, T-cell Access and NK Interactions to Predict and Improve Efficacy

CompletedOBSERVATIONAL

Enrollment

200

Participants

Timeline

Start Date

December 31, 2016

Primary Completion Date

September 1, 2022

Study Completion Date

August 30, 2023

Conditions

RCCMetastatic Renal Cell Carcinoma

Interventions

BIOLOGICAL

Immunological and tumour characterization

FFPE, blood samples (liquid biopsy, heparin and EDTA blood) performed in patients presenting a renal metastatic cancer receiving treatment as standard practice according to physician's choice (2nd or 3rd line of treatment with nivolumab, or other second line according to physician's choice)

Trial Locations (1)

80131

IRCCS Istituto Nazionale Tumori di Napoli, Naples

All Listed Sponsors

lead

National Cancer Institute, Naples

OTHER

NCT03891485 - Nivolumab in mRCC Patients: Treg Function, T-cell Access and NK Interactions to Predict and Improve Efficacy | Biotech Hunter | Biotech Hunter